Our Board

bresmed_port_013-square

Kunal Srivastava

Chief Practice Officer: Evidence Evaluation Consulting

Kunal joined BresMed in 2014 and became a Board member in 2019. He has a master’s degree in pharmacy. Kunal began his career in the health industry at Promed (now Sentiss Pharma), in R&D project management. He started developing his health economics and outcomes research (HEOR) and consulting skills at Heron (now Parexel) in systematic reviews and meta-analysis, becoming a senior consultant for the company. At BresMed, Kunal heads up the India operations; he set up the evidence review practice area, and is responsible for the 30+ members of the systematic review team. Kunal is responsible for the technical excellence of evidence reviews. He brings strong business acumen and works closely with the other Board members to set the future direction of the company, aiming to increase BresMed’s global presence while maintaining the quality and viability of the business.

In his spare time, Kunal likes to spend time with his family, read books, watch movies and unwind. Kunal has a keen interest in global affairs and the impact of technology and innovation on the modern world.

Kunal says about BresMed: “I’m proud of BresMed‘s rapid development. We are able to offer a world-class consulting service to clients due to the mentoring and training of first-class employees.”

Curriculum vitae

Employment history

2019-Present   Chief Practice Officer: Evidence Evaluation Consulting   BresMed

2016-Present   Country Head India   BresMed

2014-2019   Head of Systematic Reviews   BresMed

2007-2014   Senior Consultant   Heron (now Parexel)

2006-2007   Management Trainee R&D Project Management   Promed (now Sentiss Pharma)

 

Research interests

  • All aspects of HEOR and HTA
  • Supporting countries and geographies with different access mechanisms and partially implemented HTAs
  • Efficiencies and automation in HEOR industry
  • Evidence reviews, systematic reviews, targeted reviews, focused reviews etc.
  • Clinical, Economic, Humanistic, Epidemiology and disease burden evidence
  • Evidence generation and synthesis
  • Meta-analysis, indirect treatment comparisons and mixed treatment comparisons
  • Real world evidence
  • Clinical research

 

Therapeutic areas of expertise

  • Asthma – Conducted and lead a clinical systematic review to summarise the efficacy and safety of various interventions being administered in clinical practise. This work supported indirect and mixed treatment comparisons, an economic model and the design of a Phase III trial, and will support future submission of various molecules being developed for asthma
  • Breast cancer – Conducted and lead multiple clinical and economic systematic reviews in breast cancer with focus on overall population, metastasis to specific sites and mutation specific subgroups. These works have supported HTA submissions, analyses and economic model development
  • Bipolar disorder – Conducted and lead a suite of clinical systematic reviews and updates to generate evidence for efficacy and safety of various treatments in bipolar disorder in comparison to the client’s intervention. Mixed treatment comparisons were also conducted to quantitatively synthesise the evidence. This work was used to support the economic model and the development of Phase III trial design, and will support HTA submissions
  • Cardiac transplantation – Conducted and lead a clinical systematic review and feasibility assessment to support a molecule in cardiac transplantation. The focus of the work was impact of the acute heart rejection rate, safety and other composite outcomes. A NICE briefing booklet was prepared to support the product’s value story and to request restricted access to patients
  • COPD – Conducted and lead an economic and humanistic burden review to summarise the burden associated with COPD (special emphasis on symptomatic COPD) across various geographies such as the UK, Europe, the USA, etc. This work supported the development of an economic model and overall landscape support for various molecules being developed for COPD. An ISPOR abstract has been published, and a manuscript is under development
  • Diabetes – Conducted and lead an economic and humanistic burden review to assess the burden associated with diabetes
  • Lung cancer – Conducted and lead a clinical systematic review for lung cancer to summarise the efficacy and safety of various treatments. This work was used to support HTA submissions
  • Major depressive disorder – Conducted and lead a suite of clinical systematic reviews and updates to generate evidence for efficacy and safety of various treatments in major depressive disorder and treatment resistant major depressive disorder (different populations) in comparison to the client’s intervention. Mixed treatment comparisons were also conducted to quantitatively synthesise the evidence. This work was used to support an economic model and the development of Phase III trial design, and will support HTA submissions
  • Metastatic malignant melanoma – Conducted and lead a clinical systematic review and indirect treatment comparisons to assess the efficacy and safety of the client’s intervention in comparison to other treatments. This work was used to provide input to economic models and support global reimbursement submissions. An ISPOR abstract has been published, and a manuscript is under development
  • Multiple myeloma – Conducted and lead multiple clinical and economic systematic reviews in multiple myeloma with focus on multiple myeloma as well as metastasis to other sites. The work has been used for NICE submissions and conducting analyses
  • Neuropathic pain – Conducted and lead a clinical systematic review and mixed treatment comparison to assess the efficacy, safety and quality of life of the client’s intervention in comparison to the market leader intervention. This work was used to support the product’s value story. A manuscript is under development
  • Osteoarthritis – Conducted and lead a clinical systematic review to summarise the efficacy and safety of various treatments. This work was used to support an economic model
  • Pain management – Conducted and lead a systematic review to assess the impact of a once-daily dosage regimen in comparison to multiple dosage regimens on adherence and compliance of patients suffering with chronic conditions including neuropathic pain. This work was used to support the value story of the client’s product. A manuscript has already been published
  • Prostate cancer – Conducted and lead separate clinical systematic reviews for prostate cancer and hormone refractory metastatic prostate cancer (sub-population) to summarise the efficacy and safety of various treatments. This work was used to support HTA submissions
  • Renal cell carcinoma – Conducted and lead a clinical systematic review to summarise the efficacy and safety of various treatments. This work was used to support HTA submissions
  • Renal transplantation – Conducted and lead a clinical systematic review to support the value story of a molecule in renal transplantation. A systematic review for economic and humanistic burden of renal transplantation across various geographies was also conducted. An ISPOR abstract has also been published
  • Rheumatoid arthritis – Conducted and lead a clinical systematic review and mixed treatment comparison analyses to provide evidence for economic model development and global reimbursement submissions. Analyses were conducted for various sub-populations depending upon the previous and current treatment received by patients (e.g. DMARD failure and receiving DMARDs)
  • Schizophrenia – Conducted and lead a suite of clinical systematic reviews and updates to generate evidence for the efficacy and safety of various treatments in schizophrenia in comparison to client’s intervention. Mixed treatment comparisons were also conducted to quantitatively synthesise the evidence. This work was used to support an economic model and the development of Phase III trial design, and will support HTA submissions
  • Stem cell transplantation – Conducted and lead a targeted review to identify and summarise various treatment strategies/support strategies employed in clinical practise to enhance the response to stem cell transplantation
  • Systemic lupus erythematosus – Conducted and lead a clinical systematic review to summarise the efficacy and safety of various treatments. This work was used to support an economic model

 

Memberships

ISPOR (Europe, US and Asia)

 

Publications

View Kunal’s publication history in our database

 

Referee/Reviewer roles

  • ISPOR abstracts

 

Back to Our Board